EPISODE · Jan 17, 2023 · 56 MIN
Episode 116: Should Low-Grade Prostate Cancer Be Considered Cancer?
from Healthcare Unfiltered · host Chadi Nabhan
Scott Eggener, MD, University of Chicago, and Jonathan Epstein, MD, The Johns Hopkins Medical Institutions, join the show to debate whether Gleason Score 6 prostate cancer should be renamed to non-cancer. The trio hit on what should happen upon diagnosis and Gleason grade 6, which patients should be offered active surveillance, the benefits and risks of not calling this diagnosis “cancer,” how often and how frequently to biopsy, overscreening, and many other discussion points.Read Dr. Eggener’s editorial in the Journal of Clinical Oncology.https://ascopubs.org/doi/full/10.1200/JCO.22.00123Read Dr Epstein’s response in the Journal of Clinical Oncology.https://ascopubs.org/doi/full/10.1200/JCO.22.00926Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
Embed this episode
What this episode covers
Scott Eggener, MD, University of Chicago, and Jonathan Epstein, MD, The Johns Hopkins Medical Institutions, join the show to debate whether Gleason Score 6 prostate cancer should be renamed to non-cancer. The trio hit on what should happen upon diagnosis and Gleason grade 6, which patients should be offered active surveillance, the benefits and risks of not calling this diagnosis “cancer,” how often and how frequently to biopsy, overscreening, and many other discussion points.Read Dr. Eggener...
NOW PLAYING
Episode 116: Should Low-Grade Prostate Cancer Be Considered Cancer?
No transcript for this episode yet
Similar Episodes
No similar episodes found.